It was announced today that MSD is seeking to extend its Research & Development and Formulation building in Ballydine Co. Tipperary.
Subject to planning permission being granted, the current building will be extended by a total of 6400sqm with the addition of a new three-story extension which will contain the latest equipment and technology to support development and launch of pipeline medicines.
MSD hopes to complete design and initial construction work in 2020 and start full construction in 2021, with a view to the new building being operational and commencing production in 2023.
MSD’s Ballydine site currently has a team of approximately 500 and the planned expansion of the R&D and Formulation building will lead to the addition of approximately 20 new staff in the areas of product development, operations and quality.
In the short term, the construction project will also be supported by approximately 220 people, such as trade contractors and construction workers, peaking in 2021.
MSD Ballydine is one of MSD’s five current sites in Ireland with sister sites located in Carlow, Cork and Dublin. MSD also recently announced the conclusion of an agreement to acquire an additional site in Dunboyne.
To date, MSD has invested approximately $3 billion in its Irish operations and its annual turnover ranks MSD as one of Ireland’s top 20 companies.
Speaking this week, Plant Manager at MSD Ballydine, Brian Killen said, "We’re very excited as a team to continue to attract investment from our company and are firmly focussed on the future and the medicines of tomorrow, with the aim that Ballydine continues to play an active and ongoing role in supporting this critical area. The additional expansion is a further endorsement of the highly-skilled team we have working here in Ballydine and the important work that they do."